Immunosuppressive Effects of Tautomycetin in vivo and in vitro via T Cell-Specific Apoptosis Induction

Tautomycetin (TMC) was identified as an immunosuppressor of activated T cells. Inhibition of T cell proliferation with TMC was observed at concentrations 100-fold lower than those needed to achieve maximal inhibition with cyclosporin A (CsA). TMC specifically blocked tyrosine phosphorylation of intr...

Full description

Saved in:
Bibliographic Details
Published inProceedings of the National Academy of Sciences - PNAS Vol. 99; no. 16; pp. 10617 - 10622
Main Authors Shim, Jae-Hyuck, Lee, Heung-Kyu, Chang, Eun-Ju, Chae, Wook-Jin, Han, Jin-Hwan, Han, Duck-Jong, Morio, Tomohiro, Yang, Jung-Jin, Bothwell, Alfred, Lee, Sang-Kyou
Format Journal Article
LanguageEnglish
Published United States National Academy of Sciences 06.08.2002
National Acad Sciences
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Tautomycetin (TMC) was identified as an immunosuppressor of activated T cells. Inhibition of T cell proliferation with TMC was observed at concentrations 100-fold lower than those needed to achieve maximal inhibition with cyclosporin A (CsA). TMC specifically blocked tyrosine phosphorylation of intracellular signal mediators downstream of Src tyrosine kinases in a T cell-specific manner, leading to apoptosis due to cleavage of Bcl-2, caspase-9, caspase-3, and poly(ADP-ribose) polymerase, but not caspase-1. In TMC-treated rats that received a heterotopic cardiac allograft, the graft survived more than 160 days, comparable to graft survival in allografted rats treated with CsA. Thus, TMC, whose mechanism of action is different from that of CsA or FK506, can be used as a potent T cell-specific immunosuppressor.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
This paper was submitted directly (Track II) to the PNAS office.
J.-H.S. and H.-K.L. contributed equally to this work.
To whom reprint requests should be addressed. E-mail: sjrlee@yonsei.ac.kr.
Edited by Charles A. Janeway, Jr., Yale University School of Medicine, New Haven, CT, and approved June 11, 2002
ISSN:0027-8424
1091-6490
DOI:10.1073/pnas.162522099